| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MED from our risk checks.
MEDICLIN Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.26 |
| 52 Week High | €3.00 |
| 52 Week Low | €2.20 |
| Beta | 0.26 |
| 11 Month Change | 0% |
| 3 Month Change | -1.74% |
| 1 Year Change | -14.39% |
| 33 Year Change | -43.78% |
| 5 Year Change | -58.53% |
| Change since IPO | -79.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| MED | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -1.9% | -1.8% |
| 1Y | -14.4% | 24.7% | 13.6% |
Return vs Industry: MED underperformed the German Healthcare industry which returned 24.7% over the past year.
Return vs Market: MED underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 4.5% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MED has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 6,910 | Joachim Ramming | www.mediclin.de |
MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute, Acute, and Other Activities segments. It offers medical services in the areas of neurology, psychosomatics, orthopedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, vascular medicine, otorhinolaryngology, cardiac medicine, rheumatology, pain medicine, trauma surgery, urology, and others.
MEDICLIN Aktiengesellschaft Fundamentals Summary
| MED fundamental statistics | |
|---|---|
| Market cap | €111.15m |
| Earnings (TTM) | -€14.95m |
| Revenue (TTM) | €764.10m |
0.1x
P/S Ratio-7.4x
P/E RatioIs MED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MED income statement (TTM) | |
|---|---|
| Revenue | €764.10m |
| Cost of Revenue | €618.32m |
| Gross Profit | €145.78m |
| Other Expenses | €160.73m |
| Earnings | -€14.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 19.08% |
| Net Profit Margin | -1.96% |
| Debt/Equity Ratio | 46.7% |
How did MED perform over the long term?
See historical performance and comparison